ESMO 2017 Highlights in Sarcoma and GIST: Novel Drugs and Networks

Speaker: Sebastian Bauer

Sebastian Bauer speaks about the importance of the results presented during ESMO 2017, both from the clinical research and patient management perspective. He reports some results presented by a French group showing that the local disease control is highly significantly better when patients are treated in a reference centre.

Sebastian Bauer speaks about the importance of the results presented during ESMO 2017, both from the clinical research and patient management perspective. He reports some results presented by a French group showing that the local disease control is highly significantly better when patients are treated in a reference centre.

Filip Janku presents encouraging results about the activity of a novel pan-KIT and PDGFR-alpha inhibitor in GIST patients. This agent is more specific against KIT and less dependent on secondary resistance Mutations.

Paolo Casali reports the final analysis results of a randomised trial testing adjuvant imatinib after surgery in localised GIST patients. After more than 9 years follow-up, the study confirms that the high-risk subgroup of patients benefits from adjuvant imatinib therapy, while low- and intermediate-risk patients should not get the treatment.

Abstracts

  • LBA55 - Time to definitive failure to the first Tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial
  • 1473O - Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST)

More resources from ESMO 2017 Congress